Cancer · May 14, 2026
FDA Approves First BCL2 Inhibitor for Tough-to-Treat Mantle Cell Lymphoma
BeOne receives FDA approval for a new mantle cell lymphoma therapy, establishing an entirely new class of treatment options for pa...
Cancer · May 14, 2026
FDA Approves Two New Drug Regimens for Hard to Treat Blood Cancers
FDA approvals of Beqalzi and Inqovi represent important new treatment options for patients with mantle cell lymphoma and blood can...